Cargando…

Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models

Inflammation is a growing area of research in neurodegeneration. In Huntington's disease (HD), a fatal inherited neurodegenerative disease caused by a CAG-repeat expansion in the gene encoding huntingtin, patients have increased plasma levels of inflammatory cytokines and circulating monocytes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Träger, Ulrike, Andre, Ralph, Magnusson-Lind, Anna, Miller, James R.C., Connolly, Colúm, Weiss, Andreas, Grueninger, Stephan, Silajdžić, Edina, Smith, Donna L., Leavitt, Blair R., Bates, Gillian P., Björkqvist, Maria, Tabrizi, Sarah J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academic Press 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262574/ https://www.ncbi.nlm.nih.gov/pubmed/25447230 http://dx.doi.org/10.1016/j.nbd.2014.10.012

Ejemplares similares

A Critical Evaluation of Wet Biomarkers for Huntington’s Disease: Current Status and Ways Forward
por: Silajdžić, Edina, et al.
Publicado: (2018)

JAK/STAT Signalling in Huntington’s Disease Immune Cells
por: Träger, Ulrike, et al.
Publicado: (2013)

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
por: Silajdžić, Edina, et al.
Publicado: (2015)

No Diagnostic Value of Plasma Clusterin in Alzheimer's Disease
por: Silajdžić, Edina, et al.
Publicado: (2012)

A Metabolic Study of Huntington’s Disease
por: Nambron, Rajasree, et al.
Publicado: (2016)

A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntington’s Disease
por: Kalliolia, Eirini, et al.
Publicado: (2015)

Abnormal peripheral chemokine profile in Huntington’s disease
por: Wild, Edward, et al.
Publicado: (2011)

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease
por: Björkqvist, Maria, et al.
Publicado: (2008)

Mutant Huntingtin Does Not Affect the Intrinsic Phenotype of Human Huntington’s Disease T Lymphocytes
por: Miller, James R. C., et al.
Publicado: (2015)

Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells
por: Dobson, Lucianne, et al.
Publicado: (2016)

Longitudinal expression changes are weak correlates of disease progression in Huntington’s disease
por: Mitchell, Christopher T, et al.
Publicado: (2020)

Preface to the Special Issue on “Sleep and Circadian Disorder in Huntington’s Disease”
por: Leavitt, Blair R., et al.
Publicado: (2023)

Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Altered Intracortical T(1)-Weighted/T(2)-Weighted Ratio Signal in Huntington’s Disease
por: Rowley, Christopher D., et al.
Publicado: (2018)

Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington’s Disease
por: Mazarei, Gelareh, et al.
Publicado: (2015)

Detection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling
por: Minkova, Lora, et al.
Publicado: (2015)

Selective depletion of microglial progranulin in mice is not sufficient to cause neuronal ceroid lipofuscinosis or neuroinflammation
por: Petkau, Terri L., et al.
Publicado: (2017)

A Computational Cognitive Biomarker for Early-Stage Huntington’s Disease
por: Wiecki, Thomas V., et al.
Publicado: (2016)

Natural biological variation of white matter microstructure is accentuated in Huntington's disease
por: Gregory, Sarah, et al.
Publicado: (2018)

Characterization of Gastric Mucosa Biopsies Reveals Alterations in Huntington's Disease
por: McCourt, Andrew C, et al.
Publicado: (2015)

Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington’s Disease
por: Johnson, Eileanoir B., et al.
Publicado: (2017)

Centrally and peripherally altered glucose transporters: is it time to revisit energy deficiency as a potential treatment strategy in Huntington's disease?
por: Björkqvist, Maria
Publicado: (2023)

In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington’s disease
por: Pido-Lopez, Jeffrey, et al.
Publicado: (2018)

Neurofilament light protein in blood predicts regional atrophy in Huntington disease
por: Johnson, Eileanoir B., et al.
Publicado: (2018)

Effects of excitotoxicity in the hypothalamus in transgenic mouse models of Huntington disease
por: Henningsen, Jo B., et al.
Publicado: (2021)

Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice
por: Dickson, Elna, et al.
Publicado: (2022)

Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease
por: McColgan, Peter, et al.
Publicado: (2017)

Euploidy in somatic cells from R6/2 transgenic Huntington's disease mice
por: Petersén, Åsa, et al.
Publicado: (2005)

The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington’s disease patients
por: Neueder, Andreas, et al.
Publicado: (2017)

Magnetic resonance imaging of Huntington's disease: preparing for clinical trials
por: Klöppel, S., et al.
Publicado: (2009)

Testing a longitudinal compensation model in premanifest Huntington’s disease
por: Gregory, Sarah, et al.
Publicado: (2018)

RNA-Seq of Huntington’s disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation
por: Miller, James R. C., et al.
Publicado: (2016)

Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington’s disease by etanercept treatment
por: Pido-Lopez, Jeffrey, et al.
Publicado: (2019)

Progressive alterations in white matter microstructure across the timecourse of Huntington's disease
por: Estevez‐Fraga, Carlos, et al.
Publicado: (2023)

Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease
por: Minkova, Lora, et al.
Publicado: (2017)

Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories
por: Ross, Christopher A., et al.
Publicado: (2019)

Genetic topography and cortical cell loss in Huntington's disease link development and neurodegeneration
por: Estevez-Fraga, Carlos, et al.
Publicado: (2023)

Potential biomarkers to follow the progression and treatment response of Huntington’s disease
por: Disatnik, Marie-Hélène, et al.
Publicado: (2016)

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis
por: Byrne, Lauren M, et al.
Publicado: (2017)

A common gene expression signature in Huntington’s disease patient brain regions
por: Neueder, Andreas, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_q828g0gjl1o0e6a0p9ggu0nqpf